Paper Details

  1. Home
  2. Paper Details

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.

Author: BerghoffKarin, BestvinaChristine M, BritschgiChristian, BrunsRolf, ChenYuh-Min, ChoByoung Chul, CortotAlexis B, FelipEnriqueta, GarassinoMarina Chiara, GottfriedMaya, GriesingerFrank, HeymachJohn, IamsWade T, JohnsonMelissa, KimHye Ryun, LeXiuning, MazieresJulien, OttoGordon, PaikPaul K, ParkKeunchil, PatelJyoti D, RaskinJo, SakaiHiroshi, SchumacherKarl-Maria, SikogluElif, SmitEgbert F, ThomasMichael, VeillonRemi, ViteriSantiago, YangJames Chih-Hsin

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tepotinib showed meaningful activity in subgroups of patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) by age, prior therapies, and brain metastases, with a manageable safety profile and few treatment discontinuations.
Paper Details　
Original Abstract of the Article :
PURPOSE: Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). We present updated outcomes for clinically relevant subgroups. PATIENTS AND METHODS: This phase II, open-label, multi-cohort study o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365370/

データ提供：米国国立医学図書館（NLM）

Tepotinib for MET Exon 14 Skipping NSCLC: A Beacon of Hope

Non-small cell lung cancer (NSCLC) is a serious condition, and finding effective treatment options is a pressing need. This study focuses on tepotinib, a medication used to treat a specific type of NSCLC characterized by a mutation in the MET gene. The researchers examined the efficacy and safety of tepotinib in various subgroups of patients with this type of cancer.

A New Path for MET Exon 14 Skipping NSCLC Treatment

The study suggests that tepotinib shows promising activity in patients with MET exon 14 skipping NSCLC, regardless of age, prior treatment history, or the presence of brain metastases. The researchers found that tepotinib led to significant responses in many patients, demonstrating its potential as a valuable treatment option.

Navigating the Landscape of NSCLC Treatment: Personalized Approach

This study highlights the importance of personalized treatment approaches in NSCLC. The researchers found that tepotinib was effective across various patient subgroups, suggesting its potential to be a valuable tool in managing this complex condition.

Dr.Camel's Conclusion

This research offers a glimmer of hope for patients with MET exon 14 skipping NSCLC. Like a caravan finding a safe passage through a treacherous desert, this study provides a promising direction for treating this challenging form of cancer.

Date :
  1. Date Completed 2022-04-15
  2. Date Revised 2023-04-26
Further Info :

Pubmed ID

34789481

DOI: Digital Object Identifier

PMC9365370

Related Literature

Article Analysis
・Effects of tepotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.